Terrific Growth Picks For Tough Times: Barclays PLC, Homeserve plc & Hikma Pharmaceuticals Plc

Royston Wild discusses the earnings potential of Barclays PLC (LON: BARC), Homeserve plc (LON: HSV) and Hikma Pharmaceuticals Plc (LON: HIK).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Today I’m detailing the hot growth prospects of three FTSE stars.

International markets drive earnings

Although conditions in its home markets remain challenging, I believe the breakneck progress of Homeserve’s (LSE: HSV) international push should undergird solid earnings growth in the near term and beyond.

The emergency plumbing and electricity services provider is now the number one operator in the US, the company having seen its customer base explode 24% year-on-year between July and September. And the huge size of this market leaves Homeserve with plenty of upside to generate further gains.

And the Walsall business is also investing heavily in marketing and acquisitions to support profits expansion both at home and abroad.

The City expects Homeserve to enjoy a 9% earnings advance in the 12 months to March 2016, and a 12% rise is forecast for the following period.

Subsequent P/E ratings of 20.2 times and 17.8 times may stick above the benchmark of 15 times that indicates conventionally-attractive value, but I believe Homeserve’s terrific international opportunities fully merit such a premium.

A healthy stock star

Medicines demand remains one of life’s constants, regardless of the wider economic climate. This makes the likes of Hikma Pharmaceuticals (LSE: HIK) a solid growth pick regardless of potential hiccups in the global economy’s progress.

Indeed, a backdrop of galloping healthcare investment all over the world looks likely to keep sales of Hikma’s products moving steadily higher in the years ahead, in my opinion.

And the company remains busy on the acquisition front to bolster its already-bubbly product pipeline, not to mention its position in key markets. Hikma shelled out $2.65bn last year for Roxane Laboratories, a move that makes it the sixth biggest generics producer in the US.

The number crunchers expect the Jordan-based business to bounce back from a 23% earnings slide in 2015 with a 16% uptick in 2016, resulting in a P/E multiple of 23.3 times. With Hikma making huge strides across the globe, and particularly in the hot emerging markets of the Middle East and North Africa, I reckon the drugs giant is worthy of such heady readings.

Withdraw a small fortune

Despite expectations of further cooling in the British economy, I believe banking giant Barclays’ (LSE: BARC) remains a terrific growth selection.

Adding to fears of potential pressure on the firm’s High Street operations, the latest updates from Santander and Royal Bank of Scotland this week again highlighted the huge financial fallout heaped on Britain’s banks by the PPI mis-selling scandal of previous years.

Still, Barclays et al should take confidence from the FCA’s plans to put a lid on claims not put-in before 2018. And the company’s Transform streamlining package looks set to drive costs steadily lower in the coming years.

On top of this, the steady rise of the firm’s Barclaycard division — combined with the potential of its pan-African operations — should also win over investors concerned over possible near-term pressures on its Retail Banking arm.

The City expects Barclays to follow a predicted 24% earnings rise in 2015 with a 21% advance in 2016, leaving the company dealing on an ultra-cheap P/E rating of 8.6 times. I believe the banking goliath merits serious investor attention at these prices.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any shares mentioned. The Motley Fool UK has recommended Barclays, Hikma Pharmaceuticals, and Homeserve. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Just released: Share Advisor’s latest ‘Hold’ recommendation [PREMIUM PICKS]

In our Share Advisor newsletter service, we provide buy, sell, and hold guidance for our universe of recommendations.

Read more »